Bempedoic acid: Review of a novel therapy in lipid management.

CONCLUSION: Bempedoic acid, used alone or with ezetimibe in a fixed-dose combination formulation, may be an effective alternative to current guideline-recommended nonstatin therapies in patients who do not attain adequate LDL-C lowering with maximally tolerated statin therapy and in statin-intolerant patients at risk for atherosclerotic cardiovascular disease.
PMID: 33399194 [PubMed - in process]

Source: American Journal of Health-System Pharmacy : AJHP - January 5, 2021 Category: Drugs & Pharmacology Authors: Delevry D, Gupta EK Tags: Am J Health Syst Pharm Source Type: research